| A parallel market is flourishing around the new generation of weight-loss drugs, which have proved so effective that patients are clamoring for more than drugmakers can churn out. Last year, the U.S. Food and Drug Administration declared Ozempic and Wegovy in shortage, a designation that allows specialized pharmacies to mix up their own, cheaper versions of the blockbuster drugs. The Washington Post found more than two dozen websites that bypass doctors and pharmacies completely to sell semaglutide — the active ingredient in Ozempic and Wegovy — directly to consumers, usually with disclaimers that it's not for human use. | 
No comments:
Post a Comment